End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.71 CNY | +2.24% | +5.33% | -5.27% |
04-24 | Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator | MT |
04-18 | China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.27% | 7.65B | |
+26.10% | 661B | |
+26.74% | 566B | |
-6.55% | 352B | |
+18.89% | 332B | |
+3.88% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.15% | 145B |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Fosun Pharma Unit Gets Nod to Start Phase II Study in China of Hematologic Disorder Treatment